The Journal of Cancer Biology, Therapeutics and Clinical Oncology is a peer-reviewed, open-access scholarly journal committed to advancing the understanding, diagnosis, and treatment of cancer across all forms and stages. This journal serves as a platform for academic researchers, clinical practitioners, oncologists, pathologists, pharmacologists, and multidisciplinary teams to engage with cutting-edge developments in the realm of oncology. By facilitating the dissemination of original research and evidence-based clinical insights, the journal supports the global scientific community in addressing the complexities and challenges of cancer biology and patient care.

Cancer remains one of the most pressing medical challenges of our time, affecting millions globally and demanding continuous innovation in both research and treatment. Recognizing this urgent need, the Journal of Cancer Biology, Therapeutics and Clinical Oncology welcomes contributions that investigate molecular mechanisms, cellular pathways, tumor microenvironments, therapeutic resistance, and the translational relevance of laboratory findings to clinical practice. The journal provides a dedicated space for the convergence of basic science and clinical oncology, encouraging collaboration and knowledge-sharing between laboratory scientists and practicing physicians.

This publication embraces the full spectrum of oncology research, including but not limited to tumor genetics, epigenetics, cancer stem cells, metastasis, biomarker discovery, immunotherapy, chemotherapy, radiation therapy, and novel drug development. Special attention is given to interdisciplinary research that bridges multiple fields, such as bioinformatics, nanotechnology, personalized medicine, and pharmacogenomics. Authors are encouraged to submit studies that push the boundaries of conventional oncology paradigms while maintaining a strong foundation in scientific rigor and ethical standards.

The Journal of Cancer Biology, Therapeutics and Clinical Oncology also places emphasis on clinical outcomes, therapeutic efficacy, and patient-centered research. Articles discussing advancements in surgical oncology, radiation protocols, targeted therapies, and immuno-oncological treatments are highly valued. Case series, clinical trials, meta-analyses, and comparative studies provide meaningful insights for clinicians and policymakers striving to enhance patient care and resource allocation.

In line with the principles of open-access publishing, the journal ensures that all published content is freely accessible to readers worldwide. This model supports equitable access to scientific knowledge regardless of institutional affiliation or geographic location. By removing access barriers, the journal aims to democratize cancer research and allow for its findings to benefit both high-resource and low-resource settings.

A hallmark of the journal is its commitment to high editorial standards and rigorous peer review. Submissions undergo thorough evaluation by experts in oncology, molecular biology, pharmacology, and clinical research. The editorial board comprises seasoned professionals with deep expertise in diverse sub-disciplines of cancer research. Their contributions guide the journal’s direction and ensure the integrity, originality, and relevance of each accepted manuscript.

To maintain global relevance, the journal invites submissions from all regions and encourages studies focused on population-specific cancer trends, regional health challenges, and epidemiological disparities. Contributions from low- and middle-income countries are especially welcome, as they add valuable perspectives to the global fight against cancer and help illuminate health inequities that might otherwise go unaddressed.

The journal accepts a wide array of article types, including original research articles, review articles, systematic reviews, meta-analyses, short communications, editorials, case reports, technical notes, and clinical perspectives. Authors are advised to consult the specific submission guidelines before preparing their manuscripts.

With cancer research evolving rapidly, the journal acknowledges the importance of timely publication. Accepted articles are published online promptly to ensure that new knowledge reaches the scientific community without unnecessary delays. Each article is assigned a Digital Object Identifier (DOI) to facilitate citation and retrieval across indexing platforms and digital repositories.

Ethical compliance is a key priority for the Journal of Cancer Biology, Therapeutics and Clinical Oncology. Authors are expected to adhere to international ethical standards for research involving human participants, laboratory animals, and data integrity. Conflicts of interest, funding disclosures, and informed consent must be clearly stated in all submissions. The journal supports initiatives aimed at research transparency, including trial registrations, reproducibility checklists, and data-sharing protocols.

The journal’s editorial team actively collaborates with reviewers and contributors to ensure a constructive and efficient peer review process. Reviewers are selected based on subject expertise, publication history, and commitment to academic integrity. Feedback from reviewers is aimed at strengthening the scientific quality of submissions while encouraging early-career researchers and seasoned professionals alike to share their findings confidently.

We encourage researchers, clinicians, and academicians working in the fields of cancer biology, oncology therapeutics, and clinical oncology to consider the Journal of Cancer Biology, Therapeutics and Clinical Oncology as a trusted platform for their work. Contributions that bring clarity to complex mechanisms, highlight translational breakthroughs, or demonstrate real-world clinical applications are especially welcome. By publishing with us, authors become part of an international network dedicated to transforming cancer care through evidence-based knowledge and collaborative inquiry.

We invite you to explore the latest articles published in the journal, engage with the diverse topics presented, and contribute to the growing body of literature that seeks to redefine our approach to cancer research and treatment. Whether you are an early-career scientist, a clinical specialist, or an interdisciplinary researcher, the Journal of Cancer Biology, Therapeutics and Clinical Oncology offers an inclusive and dynamic platform for scholarly exchange.

We look forward to receiving your submissions and supporting your contributions to the ongoing dialogue in cancer science and therapy.